Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Intermediate to Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

NCT05644379 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05644379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05644379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Intermediate to Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 24, 2022
Completion date
November 30, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma that has failed at least one prior systemic therapy